Docteur MARIE-ELISE TRUCHETET
14ans d'exercice (thèse 2012)
Diplômes
🎓 DES & spécialité ordinale
- DES Rhumatologie
- Rhumatologie (SM)
🎓 Diplômes
- DE Docteur en médecine
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
Thèses universitaires
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Direction de thèses
🎓 2 thèses dirigéesA reverse clinical translation platform for the molecular stratification of vascular progression in Systemic Sclerosis (SSc)
2025Doctorant·e : Stefano Di donato
Microbiologie - immunologie🎓 BordeauxPropriétés immunologiques et non immunologiques des microparticules au cours de la sclérodermie systémique
2021Doctorant·e : Damien Leleu
Microbiologie - immunologie🎓 Bordeaux
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Activité de recherche & publications
Source : bases de données publiques (OpenAlex, PubMed).
h-index
44
h articles cités ≥ h fois chacun. Un h de 44 = 44 publications avec 44+ citations.
Citations
7 283
Publications
333
i10-index
111
Thématiques principales
- Systemic Sclerosis and Related Diseases ×146
- Rheumatoid Arthritis Research and Therapies ×63
- Systemic Lupus Erythematosus Research ×45
- Inflammatory Myopathies and Dermatomyositis ×35
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis ×33
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Bibliographie
Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database
2026ArticleRheumatology
Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score
2026ArticleAnnals of the Rheumatic Diseases
Prevalence of effective contraceptive use among patients with rheumatic diseases: a descriptive study
2026ArticleBMC Rheumatology
Nailfold video capillaroscopy predicts severe progression at three years in systemic sclerosis: Results from SCLEROCAP study
2026ArticleMicrovascular Research
French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases
2025ArticleJoint Bone Spine
Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid‐Dependent Polymyalgia Rheumatica
2025ArticleArthritis & rheumatology
Altered X-chromosome inactivation of the TLR7/8 locus and heterogeneity of pDCs in systemic sclerosis
2025ArticleJournal of Experimental Medicine
Crystalline silica on the lung–environment interface: Impact on immunity, epithelial cells, and therapeutic perspectives for autoimmunity
2025ArticleAutoimmunity Reviews
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Lieu de consultation
GROUPE HOSPITALIER PELLEGRIN - CHU
Place AMELIE RABA LEON, 33076 Bordeaux
Tarifs & secteur de conventionnement
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Prendre rendez-vous & contact
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Articles de presse (3)
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
- Connectivites : « des nouvelles voies thérapeutiques originales » - lequotidiendumedecin.fr
📰 lequotidiendumedecin.fr · 03/07/2025
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPMFRlOVM5QWtTc2RSOW9NSzREODVZa3ZEZU9tWWwyQ0lBN1BpbDJSS01LX3dpY3BlN2t4UWFXSVFkR0F0RHhldnNfTWR6UzlRckctWEl5djhHYkgtUzN5cVhKdVZWOVl3NWRNby01VFBJLWtYSnE2clB1aXd3NzVLM1lXT2pMVzF3Q05SU19iaWYtaTZseHZxRVhRc2lGMnBHZ3cxdWhTeC1pMHpKdi1FTktmVFE1VnhPRU
- Blaye. Un éclairage sur une maladie rare - hautegironde.fr
📰 hautegironde.fr · 15/01/2025
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxPSENnYzJXbXJTY1NGakNkM2Vxbi1vRUpqVUo2SVQ4eV9TYVp2MW5YNE5tZHRyMW1odXlYb1FRX2REbHp2T20tYnNiTXJ3am5KS1Y1VkY5c0k5ZjJOY052LVIxMXQtZFljZG9PZXF0ejVtal9BNlhiTkZXb3N6dUd5ZnlOaUdaVjZlVmc?oc=5" target="_blank">Blaye. Un éclairage sur une maladie rare
- Vers de nouvelles pistes thérapeutiques dans la fibrose associée à la sclérodermie - lequotidiendumedecin.fr
📰 lequotidiendumedecin.fr · 29/11/2021
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOTmdHN1ZndEtIc250YU9HQnJWLUxtbUVWYWFBUVMtR1VyMHI0cG9lQkJjejgzX0d0amY1RnlnVFdPSi1HV1A3bGg5QXRDcktrdlB0QUNpMGRnRzJ4LUVjX3lLNnI2NkNkbU0xYk5lLXprQzJRdmRwZkJIallUR2RwNVhmejFTeU9mb2xCckVCM1hJVTNQajNIeWVqMVFNZzVTeXViem93WUQ3RUF3azRqamJDaFNYbE5UZD
Top publications · les plus citées
- 2Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort
Journal of the American Heart Association · 2025
Lire l'abstract Crossref ↓
Background Systemic sclerosis (SSc) primary heart involvement (SSc‐pHI) is one of the leading causes of mortality in SSc. We aimed to evaluate risk factors for SSc‐pHI and its progression and the outcomes in the EUSTAR (European Scleroderma Trials and Research) cohort. Methods SSc‐pHI was defined according to the World Scleroderma Foundation/Heart Failure Association definition. Data from 5741 patients with SSc in the EUSTAR cohort were analyzed. Additional cardiovascular data were collected from a subcohort of 838 patients with SSc. Lasso regression was used for risk factor analyses. Kaplan–Meier estimator was used for survival analyses. Progression of SSc‐pHI was evaluated by a study definition developed by rheumatology and cardiology experts. Results Risk factors for the presence of SSc‐pHI comprised skeletal muscle atrophy (odds ratio [OR], 2.00 [95% CI, 1.00–2.68]), age (OR, 1.91 [95% CI, 1.73–2.03]), male sex (OR, 1.77 [95% CI, 1.42–2.05]), swollen joints (OR, 1.70 [95% CI, 1.47–1.98]), skeletal muscle weakness (OR, 1.38 [95% CI, 1.00–1.85]), and tendon friction rubs (OR, 1.46 [95% CI, 1.00–1.77]) (n=3276). Telangiectasia (OR, 2.10 [95% CI, 1.38–2.72]), intestinal symptoms (OR, 1.70 [95% CI, 1.04–2.42]), age (OR, 1.47 [95% CI, 1.21–1.62]), and antitopoisomerase I antibodies (OR, 1.37 [95% CI, 1.00–1.77]) were associated with an increased risk for new onset of SSc‐pHI (n=1000). Survival rate was significantly lower in patients with SSc‐pHI than in those without ( P value <0.0001, n=3768). Patients with SSc‐pHI had a lower survival rate than patients with interstitial lung disease (n=3365). Swollen joints were associated with an increased risk of progressive SSc‐pHI (OR, 2.49 [95% CI, 1.79–3.52]) (n=595). Tendon friction rubs (OR, 1.21 [95% CI, 0.94–1.90]) increased the risk of heart failure with preserved ejection fraction in patients with SSc‐pHI. Conclusions We defined progressive SSc‐pHI and identified risk factors for new onset and progression of SSc‐pHI and for SSc‐pHI‐associated heart failure with preserved ejection fraction in the largest cohort with SSc. These findings may guide patient stratification for diagnostic workup and therapy.
- 3Altered X-chromosome inactivation of the TLR7/8 locus and heterogeneity of pDCs in systemic sclerosis
The Journal of experimental medicine · 2025
Lire l'abstract Crossref ↓
Systemic sclerosis (SSc) is an autoimmune disease that has a strong female predominance. Both the X-linked TLR7 and TLR8 can induce type I IFN (IFN-I) by plasmacytoid DCs (pDCs), which can promote fibrosis. We identified five subclusters of pDCs, including ISGhigh clusters that were over-represented in SSc patients. We observed that both TLR7 and TLR8 genes escape from X chromosome inactivation (XCI) at higher frequency in pDCs of SSc patients, which was associated with changes in TLR7 protein profile. Combined DNA/RNA FISH analysis revealed that the TLR7/8 locus is preferentially located outside of the inactive X (Xi) territory when TLR7 is expressed, suggesting that higher-order loop formation is linked to TLR7/8 expression from the Xi. Furthermore, the expression levels of XIST and the transcriptional repressor SPEN were reduced in SSc pDCs. Hence, our data revealed the heterogeneity of pDCs in SSc and suggested that altered XCI at the TLR7/8 locus may contribute to the chronic IFN-I activity of pDCs in female SSc patients.
Publications scientifiques (50) — classées par pathologie
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Transversal26
▼
Transversal26
▼- What have we learned about systemic sclerosis from the EUSTAR database?
Current opinion in rheumatology · 2026 · Journal Article
Campochiaro C, Vonk MC, Osborne T, Lazzaroni MG, et al.
📚 1 cit. - Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database
Rheumatology (Oxford, England) · 2026 · Journal Article
Avanoglu-Guler A, Hughes M, De Luca G, Bellando Randone S, et al.
- Cervical cancer screening practices among patients with autoimmune and inflammatory rheumatic diseases: a descriptive cross-sectional observational study
BMC women's health · 2026 · Journal Article
Delattre C, Uthuriague M, Barnetche T, Lambert M, et al.
- Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score
Annals of the rheumatic diseases · 2026 · Journal Article
Pecher AC, Boubaya M, Allanore Y, Smith V, et al.
- Nailfold video capillaroscopy predicts severe progression at three years in systemic sclerosis: Results from SCLEROCAP study
Microvascular research · 2026 · Journal Article
Boulon C, Larrouture I, Blaise S, Mangin M, et al.
📚 1 cit.🩺 Clinique - Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort
Rheumatology (Oxford, England) · 2025 · Journal Article
Roth E, Bruni C, Petelytska L, Becker MO, et al.
📚 9 cit.🎯 RCR 4.11 - Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosis
The Lancet. Rheumatology · 2025 · Journal Article
Pauling JD, Allanore Y, Buch MH, Cutolo M, et al.
📚 3 cit. - French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases
Joint bone spine · 2025 · Journal Article
Avouac J, Fogel O, Beydon M, Frémont GM, et al.
🩺 Clinique - Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort
Rheumatology (Oxford, England) · 2025 · Journal Article
Di Donato S, Pauling JD, Ramjug S, Allanore Y, et al.
📚 4 cit.🔬→🩺 Translationnel - Deep hierarchical subtyping of multi-organ systemic sclerosis trajectories - a EUSTAR study
NPJ digital medicine · 2025 · Journal Article
Trottet C, Schürch M, Allam A, Petelytska L, et al.
📚 1 cit. - [Between the normal and the pathological: The concept of pre-disease applied to systemic autoimmune rheumatic diseases]
La Revue de medecine interne · 2025 · Journal Article
Chiche L, Truchetet ME, Cornec D, Immediato Daien C
📚 1 cit. - A comparative analysis of risk stratification tools in SSc-associated pulmonary arterial hypertension: a EUSTAR analysis
Rheumatology (Oxford, England) · 2025 · Journal Article
Bjørkekjær HJ, Bruni C, Broch K, Brunborg C, et al.
📚 3 cit. - Altered X-chromosome inactivation of the TLR7/8 locus and heterogeneity of pDCs in systemic sclerosis
The Journal of experimental medicine · 2025 · Journal Article
Du Y, Faz-Lopez B, Ah Kioon MD, Cenac C, et al.
📚 15 cit.🎯 RCR 5.33 - Crystalline silica on the lung-environment interface: Impact on immunity, epithelial cells, and therapeutic perspectives for autoimmunity
Autoimmunity reviews · 2025 · Journal Article
Galli G, Leleu D, Depaire A, Blanco P, et al.
📚 2 cit. - Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study
Joint bone spine · 2025 · Journal Article
Ladouceur A, Barnetche T, Prey S, Dutriaux C, et al.
📚 4 cit.🩺 Clinique - Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?
Arthritis care & research · 2024 · Journal Article
Deibel E, Carreira PE, Vonk M, Del Papa N, et al.
📚 2 cit.🎯 RCR 1.03 - Occupational quantitative exposure to crystalline silica, solvents and pesticides and risk of clinical forms of systemic sclerosis
Rheumatology (Oxford, England) · 2024 · Journal Article
Galli G, De Pous-Gerardin C, Hanguehard R, Berthy F, et al.
📚 6 cit.🎯 RCR 2.29🩺 Clinique - Demographic and clinical characteristics of patients with coexistence of systemic sclerosis and atopy: A cross-sectional study
Journal of the European Academy of Dermatology and Venereology : JEADV · 2024 · Letter
Archimbaud J, Barnetche T, Lazaro E, Constans J, et al.
- Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients
RMD open · 2024 · Journal Article
Didier K, Sobanski V, Robbins A, Truchetet ME, et al.
📚 5 cit.🎯 RCR 1.49🔬→🩺 Translationnel - Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis
Arthritis research & therapy · 2024 · Journal Article
Wyss A, Jordan S, Graf N, Carreira PE, et al.
📚 4 cit.🎯 RCR 1.10 - Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology
Nature communications · 2024 · Journal Article
Mattuizzi A, Sauvestre F, Fargeix T, White E, et al.
📚 13 cit.🎯 RCR 3.37 - Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis
Chest · 2024 · Journal Article
Colalillo A, Hachulla E, Pellicano C, Smith V, et al.
📚 6 cit.🎯 RCR 1.32 - The deficiency of DNASE1L3 does not affect systemic sclerosis pathogenesis in two inducible murine models of the disease
European journal of immunology · 2024 · Journal Article
Garreau A, Santa P, Dubois M, Brisou D, et al.
📚 1 cit. - Concordance and agreement between different activity scores in polymyalgia rheumatica
RMD open · 2024 · Randomized Controlled Trial
D'Agostino J, Souki A, Lohse A, Carvajal Alegria G, et al.
📚 5 cit.🎯 RCR 1.45🩺 Clinique - History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis
RMD open · 2024 · Journal Article
De Moreuil C, Diot E, Agard C, Belhomme N, et al.
🩺 Clinique - Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study
RMD open · 2023 · Observational Study
Ladouceur A, Barnetche T, Mouterde G, Tison A, et al.
📚 5 cit.🩺 Clinique
Sclérodermie6
▼
Sclérodermie6
▼- The clinical phenotype of anti-Th/To+ patients in systemic sclerosis: a case-control study within the European Scleroderma Trials and Research cohort
Therapeutic advances in musculoskeletal disease · 2026 · Journal Article
Moschetti L, Rovaris S, Bonomi F, Codes-Mendez H, et al.
- Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database
Arthritis & rheumatology (Hoboken, N.J.) · 2026 · Journal Article
Campochiaro C, Truchetet ME, Vonk M, De Luca G, et al.
📚 1 cit. - Longitudinal association between nailfold capillaroscopy and incident interstitial lung disease: A EUSTAR database analysis
Journal of scleroderma and related disorders · 2025 · Journal Article
Velauthapillai A, de Vries-Bouwstra JK, Henes J, Czirjak L, et al.
📚 1 cit. - Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database
Arthritis care & research · 2025 · Journal Article
Mongin D, Matucci-Cerinic M, Walker UA, Distler O, et al.
📚 2 cit.🩺 Clinique - Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort
Journal of the American Heart Association · 2025 · Journal Article
Györfi AH, Filla T, Polzin A, Tascilar K, et al.
📚 16 cit.🎯 RCR 7.58🔬→🩺 Translationnel - Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine
The Lancet. Rheumatology · 2023 · Journal Article
Lescoat A, Bellando-Randone S, Campochiaro C, Del Galdo F, et al.
📚 13 cit.🎯 RCR 2.05🔬→🩺 Translationnel
Épidémiologie & registres4
▼
Épidémiologie & registres4
▼- Prevalence of effective contraceptive use among patients with rheumatic diseases: a descriptive study
BMC rheumatology · 2026 · Journal Article
Uthurriague M, Delattre C, Barnetche T, Lazaro E, et al.
- Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study
Journal of autoimmunity · 2025 · Journal Article
Chaigne B, Bense A, Aubourg F, Agard C, et al.
📚 2 cit. - Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study
RMD open · 2025 · Journal Article
Triboulet F, Juge PA, Truchetet ME, Pham T, et al.
📚 6 cit.🎯 RCR 2.47🩺 Clinique - Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry
Rheumatology (Oxford, England) · 2024 · Journal Article
Faganello D, Bertrand A, Meunier P, Avouac J, et al.
📚 2 cit.
Biothérapies non-anti-TNF3
▼
Biothérapies non-anti-TNF3
▼- Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica
Arthritis & rheumatology (Hoboken, N.J.) · 2025 · Journal Article
Chevet B, Souki A, Nowak E, Carvajal-Alegria G, et al.
📚 1 cit.🩺 Clinique - Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial
BMJ open · 2025 · Clinical Trial Protocol
Pascart T, Fautrel B, Gottenberg JE, Ducoulombier V, et al.
🩺 Clinique - Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database
Annals of the rheumatic diseases · 2025 · Journal Article
Yan Q, Bruni C, Garaiman A, Mihai C, et al.
📚 7 cit.🎯 RCR 2.96
Essai clinique2
▼
Essai clinique2
▼- Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis
Rheumatology (Oxford, England) · 2024 · Journal Article
Khanna D, Kramer F, Höfler J, Ghadessi M, et al.
📚 2 cit.🩺 Clinique - Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial
The Lancet. Rheumatology · 2023 · Clinical Trial, Phase II
Distler O, Allanore Y, Denton CP, Kuwana M, et al.
📚 12 cit.🎯 RCR 1.50🩺 Clinique
JAK inhibiteurs2
▼
JAK inhibiteurs2
▼- Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry
Joint bone spine · 2026 · Letter
Truchetet ME, Prati C, Thevenot P, Bologna C, et al.
- Treatment patterns in patients with rheumatoid arthritis initiating a JAK inhibitor or a TNF inhibitor based on retail pharmacies drug-dispensing data
Joint bone spine · 2023 · Letter
Sambourg J, Gouverneur A, Bardoulat I, Schaeverbeke T, et al.
📚 2 cit.
Anti-TNF1
▼
Anti-TNF1
▼- Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort
Rheumatology (Oxford, England) · 2025 · Journal Article
Nguyen Y, Baron G, Hamamouche N, Belkhir R, et al.
📚 1 cit.🩺 Clinique
Arthrite juvénile1
▼
Arthrite juvénile1
▼- EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease
Annals of the rheumatic diseases · 2024 · Consensus Statement
Fautrel B, Mitrovic S, De Matteis A, Bindoli S, et al.
📚 114 cit.🎯 RCR 29.86🩺 Clinique
Biomarqueurs / Auto-Ac1
▼
Biomarqueurs / Auto-Ac1
▼- Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis
Rheumatology (Oxford, England) · 2024 · Journal Article
Khanna D, Kramer F, Höfler J, Ghadessi M, et al.
📚 2 cit.🩺 Clinique
csDMARDs1
▼
csDMARDs1
▼- The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort
Arthritis research & therapy · 2025 · Journal Article
Bellando-Randone S, Wilhalme H, Bruni C, Czirjak L, et al.
Économie santé1
▼
Économie santé1
▼- Comorbidity burden on mortality in patients with systemic sclerosis
RMD open · 2024 · Journal Article
Fauthoux T, Brisou D, Lazaro E, Seneschal J, et al.
📚 3 cit.🎯 RCR 1.06🩺 Clinique
Fièvres auto-inflammatoires1
▼
Fièvres auto-inflammatoires1
▼- Prevalence estimation of a rare disease with the French National Rare Disease Registry: example of TNF receptor associated periodic syndrome (TRAPS)
Orphanet journal of rare diseases · 2025 · Journal Article
Subervie A, Elhani I, Labouret M, Georgin-Lavialle S, et al.
Recommandations1
▼
Recommandations1
▼- Standardized reporting for systematic global evaluation of axial spondyloarthritis: An evidence-based and consensus-driven initiative
Joint bone spine · 2024 · Consensus Statement
Ruyssen-Witrand A, Caillet-Portillo D, Najm A, Fogel O, et al.
📚 1 cit.
Revue / méta-analyse1
▼
Revue / méta-analyse1
▼- Frequency of irritable bowel syndrome in spondyloarthritis: a multicentric cross-sectional study and meta-analysis
RMD open · 2024 · Systematic Review
Bernard J, Barnetche T, Amory C, Despres J, et al.
📚 5 cit.🎯 RCR 1.23
